The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment

Garrison LP, Wang ST, Huang H, Ba-Mancini A, Shi H, Chen K, Korves C, Dhawan R, Cakana A, van de Velde H, Corzo D, Duh MS

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
23299777

DOI
10.1634/theoncologist.2011-0380

Indexing Status
Subject indexing assigned by NLM

MeSH
Aged; Antineoplastic Combined Chemotherapy Protocols /administration & dosage /economics; Boronic Acids /administration & dosage; Bortezomib; Controlled Clinical Trials as Topic; Cost-Benefit Analysis /economics; Female; Humans; Male; Markov Chains; Melphalan /administration & dosage; Multiple Myeloma /drug therapy /economics /pathology; Neoplasm Staging; Prednisone /administration & dosage; Pyrazines /administration & dosage; Thalidomide /administration & dosage /analogs & derivatives; United States

AccessionNumber
22013008648

Date bibliographic record published
20/03/2013